Display options
Cite
Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem. 2008;8(7):702-10doi: 10.2174/138955708784567421.
Hale, C., & Wang, M. (2008). Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini reviews in medicinal chemistry, 8(7), 702-10. https://doi.org/10.2174/138955708784567421
Hale, Clarence, and Wang, Minghan. "Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes." Mini reviews in medicinal chemistry vol. 8,7 (2008): 702-10. doi: https://doi.org/10.2174/138955708784567421
Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem. 2008 Jun;8(7):702-10. doi: 10.2174/138955708784567421. PMID: 18537725.
Copy Download .nbib Format: NLM
Share it on

Mini Rev Med Chem. 2008 Jun;8(7):702-10. doi: 10.2174/138955708784567421.

Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes.

Mini reviews in medicinal chemistry

Clarence Hale, Minghan Wang

Affiliations

  1. Department of Metabolic Disorders, Amgen Inc., One Amgen Center Drive, Mail Stop 29-1-A, Thousand Oaks, CA 91320, USA.

PMID: 18537725 DOI: 10.2174/138955708784567421

Abstract

Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11beta-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.

Substances

MeSH terms

Publication Types